Driving Ex Vivo Expansion of Allogeneic CAR Cells Through Rapamycin-Activated Cytokine Signalling

Time: 2:45 pm
day: Day 2 - Track C - Afternoon


  • The Rapamycin Activated Cytokine Receptor (RACR) platform can be leveraged for cell therapy both in vivo and ex vivo
  • In vivo the RACR provides controlled proliferation via rapamycin-mediated IL-2/IL-15 cytokine signalling and protection of RACR-expressing cells from the host immune system by rapamycin tolerisation
  • Ex vivo the RACR can be leveraged to expand cells independent of endogenous cytokine receptor expression